

# WEEKLY COMPASS

## Weekly Alerts You Can Use!

### CORPORATE ACTIONS

Stocks	Ex-Date	Purpose	Amount (Rs)	Record Date
BAMBINO AGRO INDUSTRIES LTD.	21 Dec 2021	Final Dividend	1.60	22 Dec 2021
INDIA FINSEC LTD.	22 Dec 2021	E.G.M.	-	-
POWER GRID CORPORATION OF INDIA LTD.	22 Dec 2021	Interim Dividend	4.00	23 Dec 2021
POWER GRID CORPORATION OF INDIA LTD.	22 Dec 2021	Special Dividend	3.00	23 Dec 2021
PRECISION WIRES INDIA LTD.	22 Dec 2021	Stock Split From Rs.5/- to Rs.1/-	-	23 Dec 2021
Brightcom Group Ltd	23 Dec 2021	Final Dividend	0.05	-
CAN FIN HOMES LTD.	23 Dec 2021	Interim Dividend	1.50	24 Dec 2021
Hi-Klass Trading and Investment Ltd	23 Dec 2021	Stock Split From Rs.10/- to Rs.5/-	-	24 Dec 2021
HINDUSTAN EVEREST TOOLS LTD.	23 Dec 2021	Stock Split From Rs.10/- to Rs.2/-	-	24 Dec 2021
Neogen Chemicals Ltd	23 Dec 2021	E.G.M.	-	-
PTL ENTERPRISES LTD.	23 Dec 2021	Stock Split From Rs.2/- to Rs.1/-	-	24 Dec 2021
Rajnish Wellness Ltd	23 Dec 2021	Bonus issue 5:4	-	24 Dec 2021
RAMINFO LIMITED	23 Dec 2021	Interim Dividend	0.50	24 Dec 2021
Manomay Tex India Ltd	24 Dec 2021	E.G.M.	-	-
SHEETAL DIAMONDS LTD.	24 Dec 2021	Stock Split From Rs.10/- to Rs.5/-	-	27 Dec 2021

### OFFER TO BUY

Company name	Start Date	Close Date	Offer Price (Rs.)	Proposed Acquisition (No. of shares)	CMP (Rs.)
PUNIT COMMERCIALS LTD	16-Dec-21	29-Dec-21	65.00	62,400	-
S H KELKAR AND COMPANY LTD	15-Dec-21	28-Dec-21	210.00	29,00,000	152.40
MRUGESH TRADING LTD	14-Dec-21	27-Dec-21	12.50	62,800	-
MAITRI ENTERPRISES LTD	13-Dec-21	24-Dec-21	10.80	11,44,000	11.58
DATASOFT APPLICATION SOFTWARE (INDIA) LTD	09-Dec-21	22-Dec-21	3.25	2,94,280	-
AKSHARCHEM (INDIA) LTD	08-Dec-21	21-Dec-21	590.00	1,69,491	452.90

### Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	16985	16376	17379	17725	16245	16401-17225	Sell between 17011-17025 zone. Targets at 17805/18001. Stop at 17275.
BANK NIFTY	35619	33785	37001	38166	35734	33951-36301	Sell between 35801-35851 zone. Targets at 34201/33785. Stop at 37001.

### Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
DR REDDY'S LAB	4517	4445	4801	4716	4900	Negative	DR REDDYS LAB has been a major underperformer from the Pharma space. A probable double top pattern on the weekly charts followed by bearish candles on the monthly charts plus a bearish engulfing pattern on the daily charts and most importantly, the momentum oscillators signaling major weakness. Establishing short positions at CMP should be the preferred trading strategy, targeting 4445 and then aggressive targets seen at 4135-4150 zone. Stop above 4801. Holding Period: 1-2 Months.

Incorporated in the year 1984, **Dr. Reddy's Laboratories Ltd (DRL)** is an Indian pharmaceutical manufacturer with portfolio including pharmaceutical generics, 60+ APIs, custom pharmaceutical services, biosimilar, diagnostic kits and differentiated formulations. DRL has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe.

# Dr Reddy's (DRL) revenue consists of US (37%), India (18%), Russia and CIS (12%), Europe (8%), RoW (6%) and API (16.8%).

# Revenues from Emerging Markets at Rs. 1,300cr (+50% YoY and +42% QoQ) particularly from Russia, Romania, CIS countries.

# DRL delivered a miss on earnings for the quarter ending Sept 2021, Sales of Pharmaceutical Services segment has gone down 1.62% to Rs 1,018.70 crore

# Pricing pressure witnessed on some key products – Atrovastatin, Metoprolol, Liposomal Doxorubicin, Buprenorphine and Naloxone

# DRL's COVID-19 products launched until now, including Sputnik V vaccine, Remdesivir, Avigan (Favipiravir), 2-deoxy-D-glucose (2-DG) in India as well as overseas. Currently, the company is conducting clinical trials for Sputnik Light, Molnupiravir and is also developing several other COVID drugs for treatment ranging from mild to severe conditions.

The street will also spy with one big eye on the uncertainty evolving around Indian economy amidst general concerns about a new strain of COVID-19 – B.1.1.529, which is assigned the Greek letter "Omicron" by the World Health Organization (WHO) – possesses several deadly mutations and was identified recently in Africa, with cases detected in Hong Kong and Europe as well. Risk likely to prevail amidst slower than anticipated production of the second dose of Sputnik V, heavy cold storage requirements, pending WHO approval, and low demand at private hospitals have put brakes on the complete rollout of the Russian vaccine in India.

More than six months have passed but Sputnik has not been yet commercially available across India. Out of India's total 116 crore vaccinations, only 11.13 lakh doses were that of Sputnik V.

Technically, Dr. Reddy's Laboratories Ltd (DRL) stock price pattern appears ugly at current levels.

Technically speaking, the biggest negative catalyst is prevailing overbought technical conditions as the recent down trend in the stock price could trigger some more corrective declines and also on backdrop ugly looking charts, there is limited room for upside. The 200-DMA of the stock is around 4899 levels.

Firstly, overbought technical conditions prevail on the daily charts on backdrop of a probable dark cloud cover pattern on the monthly charts. The momentum oscillators are seen shifting in sell mode signaling further sharp corrective down move. The stock price has already signaled a break down from a "lower consolidation zone" on the daily — confirmation of the same below 4445 mark. Aggressive downside risk below a 4445 close is at 4135-4150 zone.

Establishing short positions at CMP should be the preferred trading strategy, targeting 4445 and then aggressive targets seen at 4135-4150 zone. Stop above 4801. Holding Period: 1-2 Months.

Daily Chart of DR REDDY'S LAB:



### Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102